MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma

Anna Sapino, Massimo Bongiovanni, Paola Cassoni, Luisella Righi, Riccardo Arisio, Silvia Deaglio, Fabio Malavasi

Research output: Contribution to journalArticle

Abstract

Extracellular matrix-degrading enzymes are crucial for cancer metastases. One group of enzymes that has been increasingly implicated in the breakdown of the extracellular matrix, and hence the intravasation and dissemination of tumour cells, is the family of metalloproteinases. In the recent past, increasing efforts have led to the development of more or less specific matrix metalloproteinase (MMP) inhibitors. Data concerning the molecular nature and timing of the contribution of MMPs to tumour spread is of paramount importance in clarifying which MMP is an appropriate target for more selective MMP inhibition in future tumour therapy. This study immunohistochemically characterized the expression patterns of MMP-2, -3, and -9 in 26 uveal melanomas. Forty-six per cent of the uveal melanomas expressed MMP-2 and/or MMP-9. MMP-3 expression was seen in 17 out of 26 uveal melanomas. MMP-9, previously shown to play an important part in tumour dissemination, was predominantly present in epithelioid melanomas (71.4%) or the epithelioid portion of mixed cell uveal melanomas (67%), whereas only one out of ten spindle cell melanomas showed MMP-9 expression (10%). MMP-2 and MMP-9 expression was associated with a significantly higher incidence of metastatic disease. The survival rate of patients with MMP-2-positive melanomas was 31% vs. 85% for patients with MMP-2-negative (p

Original languageEnglish
Pages (from-to)201-206
Number of pages6
JournalJournal of Pathology
Volume194
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Matrix Metalloproteinases
Melanoma
Matrix Metalloproteinase 3
Neoplasms
Extracellular Matrix
Matrix Metalloproteinase Inhibitors
Metalloproteases
Enzymes
Survival Rate
Uveal melanoma
Neoplasm Metastasis
Incidence

Keywords

  • Epithelioid cell melanoma
  • Metastasis
  • MMP-2
  • MMP-3
  • MMP-9
  • TIMP-1
  • TIMP-2
  • Uveal melanoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. / Sapino, Anna; Bongiovanni, Massimo; Cassoni, Paola; Righi, Luisella; Arisio, Riccardo; Deaglio, Silvia; Malavasi, Fabio.

In: Journal of Pathology, Vol. 194, No. 2, 2001, p. 201-206.

Research output: Contribution to journalArticle

Sapino, Anna ; Bongiovanni, Massimo ; Cassoni, Paola ; Righi, Luisella ; Arisio, Riccardo ; Deaglio, Silvia ; Malavasi, Fabio. / MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. In: Journal of Pathology. 2001 ; Vol. 194, No. 2. pp. 201-206.
@article{14c02b7761c1439193f655f66484c596,
title = "MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma",
abstract = "Extracellular matrix-degrading enzymes are crucial for cancer metastases. One group of enzymes that has been increasingly implicated in the breakdown of the extracellular matrix, and hence the intravasation and dissemination of tumour cells, is the family of metalloproteinases. In the recent past, increasing efforts have led to the development of more or less specific matrix metalloproteinase (MMP) inhibitors. Data concerning the molecular nature and timing of the contribution of MMPs to tumour spread is of paramount importance in clarifying which MMP is an appropriate target for more selective MMP inhibition in future tumour therapy. This study immunohistochemically characterized the expression patterns of MMP-2, -3, and -9 in 26 uveal melanomas. Forty-six per cent of the uveal melanomas expressed MMP-2 and/or MMP-9. MMP-3 expression was seen in 17 out of 26 uveal melanomas. MMP-9, previously shown to play an important part in tumour dissemination, was predominantly present in epithelioid melanomas (71.4{\%}) or the epithelioid portion of mixed cell uveal melanomas (67{\%}), whereas only one out of ten spindle cell melanomas showed MMP-9 expression (10{\%}). MMP-2 and MMP-9 expression was associated with a significantly higher incidence of metastatic disease. The survival rate of patients with MMP-2-positive melanomas was 31{\%} vs. 85{\%} for patients with MMP-2-negative (p",
keywords = "Epithelioid cell melanoma, Metastasis, MMP-2, MMP-3, MMP-9, TIMP-1, TIMP-2, Uveal melanoma",
author = "Anna Sapino and Massimo Bongiovanni and Paola Cassoni and Luisella Righi and Riccardo Arisio and Silvia Deaglio and Fabio Malavasi",
year = "2001",
doi = "10.1002/1096-9896(200106)194:2<201::AID-PATH840>3.0.CO;2-O",
language = "English",
volume = "194",
pages = "201--206",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma

AU - Sapino, Anna

AU - Bongiovanni, Massimo

AU - Cassoni, Paola

AU - Righi, Luisella

AU - Arisio, Riccardo

AU - Deaglio, Silvia

AU - Malavasi, Fabio

PY - 2001

Y1 - 2001

N2 - Extracellular matrix-degrading enzymes are crucial for cancer metastases. One group of enzymes that has been increasingly implicated in the breakdown of the extracellular matrix, and hence the intravasation and dissemination of tumour cells, is the family of metalloproteinases. In the recent past, increasing efforts have led to the development of more or less specific matrix metalloproteinase (MMP) inhibitors. Data concerning the molecular nature and timing of the contribution of MMPs to tumour spread is of paramount importance in clarifying which MMP is an appropriate target for more selective MMP inhibition in future tumour therapy. This study immunohistochemically characterized the expression patterns of MMP-2, -3, and -9 in 26 uveal melanomas. Forty-six per cent of the uveal melanomas expressed MMP-2 and/or MMP-9. MMP-3 expression was seen in 17 out of 26 uveal melanomas. MMP-9, previously shown to play an important part in tumour dissemination, was predominantly present in epithelioid melanomas (71.4%) or the epithelioid portion of mixed cell uveal melanomas (67%), whereas only one out of ten spindle cell melanomas showed MMP-9 expression (10%). MMP-2 and MMP-9 expression was associated with a significantly higher incidence of metastatic disease. The survival rate of patients with MMP-2-positive melanomas was 31% vs. 85% for patients with MMP-2-negative (p

AB - Extracellular matrix-degrading enzymes are crucial for cancer metastases. One group of enzymes that has been increasingly implicated in the breakdown of the extracellular matrix, and hence the intravasation and dissemination of tumour cells, is the family of metalloproteinases. In the recent past, increasing efforts have led to the development of more or less specific matrix metalloproteinase (MMP) inhibitors. Data concerning the molecular nature and timing of the contribution of MMPs to tumour spread is of paramount importance in clarifying which MMP is an appropriate target for more selective MMP inhibition in future tumour therapy. This study immunohistochemically characterized the expression patterns of MMP-2, -3, and -9 in 26 uveal melanomas. Forty-six per cent of the uveal melanomas expressed MMP-2 and/or MMP-9. MMP-3 expression was seen in 17 out of 26 uveal melanomas. MMP-9, previously shown to play an important part in tumour dissemination, was predominantly present in epithelioid melanomas (71.4%) or the epithelioid portion of mixed cell uveal melanomas (67%), whereas only one out of ten spindle cell melanomas showed MMP-9 expression (10%). MMP-2 and MMP-9 expression was associated with a significantly higher incidence of metastatic disease. The survival rate of patients with MMP-2-positive melanomas was 31% vs. 85% for patients with MMP-2-negative (p

KW - Epithelioid cell melanoma

KW - Metastasis

KW - MMP-2

KW - MMP-3

KW - MMP-9

KW - TIMP-1

KW - TIMP-2

KW - Uveal melanoma

UR - http://www.scopus.com/inward/record.url?scp=0034969317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034969317&partnerID=8YFLogxK

U2 - 10.1002/1096-9896(200106)194:2<201::AID-PATH840>3.0.CO;2-O

DO - 10.1002/1096-9896(200106)194:2<201::AID-PATH840>3.0.CO;2-O

M3 - Article

C2 - 11400149

AN - SCOPUS:0034969317

VL - 194

SP - 201

EP - 206

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 2

ER -